JPS59108800A - 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子 - Google Patents

誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子

Info

Publication number
JPS59108800A
JPS59108800A JP57218134A JP21813482A JPS59108800A JP S59108800 A JPS59108800 A JP S59108800A JP 57218134 A JP57218134 A JP 57218134A JP 21813482 A JP21813482 A JP 21813482A JP S59108800 A JPS59108800 A JP S59108800A
Authority
JP
Japan
Prior art keywords
fine particles
action
estracyte
reactive functional
estrasite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57218134A
Other languages
English (en)
Japanese (ja)
Other versions
JPS64926B2 (enExample
Inventor
Masaru Yoshida
勝 吉田
Masaharu Asano
雅春 浅野
Isao Kaetsu
嘉悦　勲
Katsuyuki Nakai
中井　克幸
Eiju Yamanaka
山中　英寿
Keizo Shida
志田　圭三
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Atomic Energy Agency
Original Assignee
Japan Atomic Energy Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Atomic Energy Research Institute filed Critical Japan Atomic Energy Research Institute
Priority to JP57218134A priority Critical patent/JPS59108800A/ja
Priority to PCT/SE1983/000440 priority patent/WO1984002270A1/en
Priority to EP84900138A priority patent/EP0128186A1/en
Publication of JPS59108800A publication Critical patent/JPS59108800A/ja
Publication of JPS64926B2 publication Critical patent/JPS64926B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP57218134A 1982-12-13 1982-12-13 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子 Granted JPS59108800A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP57218134A JPS59108800A (ja) 1982-12-13 1982-12-13 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
PCT/SE1983/000440 WO1984002270A1 (en) 1982-12-13 1983-12-09 Microfine particles having target-seeking properties
EP84900138A EP0128186A1 (en) 1982-12-13 1983-12-09 Microfine particles having target-seeking properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57218134A JPS59108800A (ja) 1982-12-13 1982-12-13 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子

Publications (2)

Publication Number Publication Date
JPS59108800A true JPS59108800A (ja) 1984-06-23
JPS64926B2 JPS64926B2 (enExample) 1989-01-10

Family

ID=16715166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57218134A Granted JPS59108800A (ja) 1982-12-13 1982-12-13 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子

Country Status (3)

Country Link
EP (1) EP0128186A1 (enExample)
JP (1) JPS59108800A (enExample)
WO (1) WO1984002270A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0533193U (ja) * 1991-08-07 1993-04-30 慶次郎 山岡 デイスプレイパネル

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617292A (ja) * 1984-06-20 1986-01-13 Japan Atom Energy Res Inst 制癌剤を結合させたエストラサイト系化合物を製造する方法
AUPN327695A0 (en) 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
WO1998033486A1 (en) * 1997-01-30 1998-08-06 Quadrant Healthcare (Uk) Limited Microparticles and their use in cancer treatment
WO2001010446A2 (en) * 1999-08-09 2001-02-15 Pharmacia & Upjohn S.P.A. Formulations for parenteral use of estramustine phosphate and albumin
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH594444A5 (enExample) * 1972-12-04 1978-01-13 Gerd Birrenbach
JPS5585516A (en) * 1978-11-27 1980-06-27 Japan Atom Energy Res Inst Method of preparing polymer composition containing carcinostatic substance
EP0040506B1 (en) * 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0533193U (ja) * 1991-08-07 1993-04-30 慶次郎 山岡 デイスプレイパネル

Also Published As

Publication number Publication date
EP0128186A1 (en) 1984-12-19
JPS64926B2 (enExample) 1989-01-10
WO1984002270A1 (en) 1984-06-21

Similar Documents

Publication Publication Date Title
US6254890B1 (en) Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
Pitto-Barry Polymers and boron neutron capture therapy (BNCT): A potent combination
US5834556A (en) Graft copolymer of polycationic species and water-soluble polymers, and uses therefor
CN113827567B (zh) 载小分子药聚合物囊泡在制备治疗急性淋系白血病药物中的应用
KR20130067157A (ko) ｐＨ 감응형 약물 담지 탄산칼슘 복합 나노입자, 이의 제조방법 및 이를 포함하는 약물 전달체 조성물
JPS617292A (ja) 制癌剤を結合させたエストラサイト系化合物を製造する方法
JPS59108800A (ja) 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
JP4847318B2 (ja) 荷電開始剤ポリマーおよび使用法
WO2023104053A1 (zh) 一种氧化还原型纳米颗粒和活细胞载体及其应用
CN116003683B (zh) 纳米凝胶阻塞材料、基于RES-blockade策略的肿瘤多步疗法系列药物及其应用
CN101181225A (zh) 纳米聚合物胶束药物传递系统和制备方法及应用
GB2240547A (en) New compositions
CN114081953B (zh) 一种前药树状聚合物纳米载体及其制备方法与应用
CN112451677B (zh) 一种用于肺部疾病治疗的药物制剂及其制备方法
CN101401792B (zh) 一种纳米囊及纳米囊复合微球的制备方法
CN106729749B (zh) 一种能够实现基因和药物共载的传递系统及其制备方法与应用
CN105168151B (zh) 一种氧化还原敏感型纳米靶向载体的制备方法
JP2006522802A (ja) リガンド結合開始剤ポリマーおよび使用法
CN115737895B (zh) 一种用于抗肝癌的磁性栓塞微球及其制备方法与应用
WO2010026781A1 (ja) 粒子およびその製造方法、ならびにゲル
CN111265494A (zh) 具有肿瘤放化疗协同增敏效应的载药微球及其制备方法
CN118440242A (zh) 一种含胆固醇聚合物修饰的脂质、阿霉素脂质体及其制备方法与应用
CN114522249A (zh) 一种含锰涂层磷酸钙微球的制备方法及其在药物载体方面的应用
CN116270459B (zh) 一种雷公藤红素前药递送明胶胶束及其制备方法
US20020044973A1 (en) Microparticles and their use in cancer treatment